MARY PLAYDON

(She/Her)

Associate Professor

Nutrition & Integrative Physiology

  • Associate Professor
    Nutrition & Integrative Physiology
  • Adjunct Associate Professor
    Population Health Science
  • 801.213.6264 (Work)
  • University of Utah, Nutrition and Integrative Physiology, HCI Research South 4511, 2000 Circle of Hope Dr, Salt Lake City, UT, 84109, United States

RESEARCH INTERESTS

Dr. Playdon's research focuses on the role of modifiable lifestyle factors like diet and obesity in the development of cancer and survival after cancer diagnosis. With her collaborators, she has done cutting-edge research on developing dietary biomarkers using metabolomics to improve dietary measurement, and understand the mechanisms underlying dietary relationships with disease. Her research program at the University of Utah is further characterizing promising dietary biomarkers, exploring metabolic phenotype in the development of female and other diet-related cancers like colorectal cancer, and applying nutritional metabolomics to studies of cancer survivorship, including cohort studies and dietary interventions.

Cancer patients, and the public, have a strong interest in what dietary factors might prevent cancer or improve survival after cancer diagnosis. Many questions remain, since dietary measurement is prone to errors that can make it difficult to detect diet-cancer signals. Dr. Playdon's recent work validating dietary biomarkers has uncovered several markers with potential to be considered 'gold standard' that could be used to improve the measurement of diet. She also uncovered the trove of information available by measuring metabolites from a small blood sample: what a person ate, how that food might have been processed and prepared, and how their metabolism has responded to diet. Since many large observational studies have thousands or tens of thousands of patient samples in storage, nutritional metabolomics could be conducted with immediate effect and applied to studies of diseases like cancer on a very large-scale. This has the potential to dramatically shift the landscape of nutritional research.

Many cancer survivors, particularly survivors of obesity-related cancers, are at high risk of developing comorbidities after cancer diagnosis, including diabetes and cardiovascular disease. Dr. Playdon is developing studies to explore the etiology of metabolic abnormalities and comorbidities among cancer patients using molecular epidemiology approaches. Furthermore, she is studying strategies to improve metabolic health among cancer patients including modifying dietary pattern, meal timing, and lifestyle interventions that include combinations of diet and physical activity. 

Having counseled hundreds of women that are living with a diagnosis of cancer on diet and lifestyle change as a research dietitian continues to inspire Dr. Playdon's passion for making discoveries related to the role of nutrition in both preventing cancer, and prolonging life and improving the quality of life of cancer survivors.

GRANTS

  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    1 Sep 2026 - 15 Mar 2027
  • EXTERNAL GRANT OR CONTRACT
    TARGETING DIET-DRIVEN INFLAMMATION FOR COLORECTAL CANCER PREVENTION IN HIGH-RISK ADULTS: A BIOMARKER-GUIDED APPROACH
    2 Jun 2026 - 31 May 2031
  • EXTERNAL GRANT OR CONTRACT
    CHRONO-CUISINE: INVESTIGATING MEAL TIMING PATTERNS AND CANCER SUSCEPTIBILITY
    1 Jun 2026 - 31 May 2028
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    1 Sep 2025 - 31 Aug 2026
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    1 Sep 2025 - 31 Aug 2026
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2025 - 31 Dec 2025
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    1 Sep 2025 - 31 Aug 2026
  • EXTERNAL GRANT OR CONTRACT
    HUNTSMAN CANCER INSTITUTE POST-BACCALAUREATE PROGRAM IN CANCER RESEARCH
    1 Jan 2025 - 31 Dec 2027
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2024 - 31 Aug 2025
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2024 - 31 Aug 2025
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2024 - 31 Aug 2025
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    ROLE OF THE INFLAMMATORY DIETARY PATTERN IN GUT AND COLON TISSUE MICROBIOMES AND IMPACT ON SURVIVAL OUTCOMES AMONG COLORECTAL CANCER PATIENTS
    THE OHIO STATE UNIVERSITY1 Jun 2024 - 31 May 2026
    THE OHIO STATE UNIVERSITY
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2023 - 31 Aug 2024
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2023 - 31 Aug 2024
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2023 - 31 Aug 2024
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    NIH NATIONAL CANCER INSTITUTE1 Sep 2023 - 31 Aug 2024
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    2 Sep 2022 - 31 Aug 2023
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    2 Sep 2022 - 31 Aug 2023
  • EXTERNAL GRANT OR CONTRACT
    CERAMIDES AS NOVEL DRIVERS OF METABOLIC DYSFUNCTION AND COLORECTAL CANCER
    2 Sep 2022 - 31 Aug 2023
  • EXTERNAL GRANT OR CONTRACT
    National Cancer Institute14 Jun 2022 - 31 May 2025
    People funded by this grant:
    • PLAYDON MC,
    • OSE J
    National Cancer Institute
  • EXTERNAL GRANT OR CONTRACT
    GLOBAL METABOLOMICS PROFILING, DIETARY FACTORS, AND COLORECTAL CANCER RISK IN THE NIH-CONSORTIUM OF METABOLOMICS STUDIES (COMETS)
    NIH NATIONAL CANCER INSTITUTE16 Mar 2022 - 31 May 2025
    NIH NATIONAL CANCER INSTITUTE
  • EXTERNAL GRANT OR CONTRACT
    METABOLOMIC PROFILES OF INSULINEMIC DIETARY PATTERNS AND COLORECTAL CANCER RISK: A CONSORTIUM OF METABOLOMICS STUDIES (COMETS) ANALYSIS
    OHIO STATE UNIVERSITY RESEARCH FNDTN1 Jan 2022 - 31 Dec 2025
    OHIO STATE UNIVERSITY RESEARCH FNDTN
  • EXTERNAL GRANT OR CONTRACT
    INFLAMMATORY LIPID MEDIATORS AND AROMATASE INHIBITOR-ASSOCIATED ARTHRALGIAS IN BREAST CANCER
    UNIVERSITY OF MICHIGAN1 Sep 2021 - 31 Aug 2024
    UNIVERSITY OF MICHIGAN
  • EXTERNAL GRANT OR CONTRACT
    PLAYDON_OHIO SUB_03.31.20
    OHIO STATE UNIVERSITY RESEARCH1 Jan 2021 - 31 Dec 2021
    OHIO STATE UNIVERSITY RESEARCH
  • EXTERNAL GRANT OR CONTRACT
    INTEGRATING GENOMICS, METABOLOMICS AND BEHAVIORS TO UNDERSTAND MECHANISMS OF CANCER-RELATED FATIGUE
    CEDARS SINAI MEDICAL CENTER28 May 2020 - 31 Mar 2025
    CEDARS SINAI MEDICAL CENTER